04th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160022514 | Quick Release Clamp for Stretcher Carriers and the Like - A stretcher clamp mountable on a gurney designed to be quickly opened for inserting a cylindrical stretcher handle and then quickly closed. When closed, the stretcher clamp remains in a closed, locked position regardless of bumps and jolts received when the gurney is moved across rough terrain. When the gurney reaches its destination, the novel stretcher clamps are easily and reliably openable to release the stretcher handle therefrom. Unlike stretcher clamps of the prior art, the stretcher clamp of the invention is not prone to jamming caused by bending or other distortions during transit. The clamp has two major components: an elongated latch handle and an elongated handle retainer, both rotatively mounted in a rigid, U-shaped frame or base. These two components are interconnected by a linkage assembly that is rotatively connected to the elongated latch handle and the elongated handle retainer and positioned therebetween. | 2016-01-28 |
20160022515 | Military Stretcher System - The present invention relates to a military stretcher system. The system includes a military hand-carried stretcher. An adaptor is provided for adapting the stretcher to fasten to a military transportation stretcher holder, typically used on vessels and in vehicles and in aircraft. Advantageously, the adaptor may adapt the stretcher to fasten to the holder (e.g. a racking system) conventionally used to hold a known NATO type stretcher. | 2016-01-28 |
20160022516 | OBSTACLE TRAVERSING WHEELCHAIR - A wheelchair suspension is provided. The wheelchair suspension includes a frame, a front caster pivot arm, a drive assembly, and a rear caster. The front caster pivot arm is pivotally connected to the frame. The front caster is coupled to a front end of the front caster pivot arm. The drive assembly is pivotally connected to the front caster pivot arm. The drive assembly comprises a drive wheel and a motor that drives the drive wheel. Torquing of the drive wheel by the motor in a forward direction causes the drive assembly to pivot with respect to the front caster pivot arm such that the drive wheel moves forward toward the front caster and a distance between a support surface and the connection between of the drive assembly and the front caster pivot arm increases. | 2016-01-28 |
20160022517 | MOBILITY-ASSISTANCE APPARATUS AND METHOD OF USING SAME - A mobility-assistance apparatus is disclosed. The apparatus comprises a wheelchair with a seat and frame and a walker coupled to the wheelchair. The walker is configured to be integrated into the wheelchair, such that the walker width is about the same as the wheelchair width. A wheelchair assistant is also disclosed which includes a walker and a seat lift mechanism, the wheelchair assistant being capable of integrated into a wheel chair such that the walker width is about the same as the wheelchair width. A mobility assistant apparatus is disclosed wherein the wheelchair assistant including a walker and seat lift mechanism is integrated into a wheelchair. | 2016-01-28 |
20160022518 | ELECTRIC BED - An electric bed includes a base frame, a movable frame slidably disposed on the base frame and moveable backward and forward, a back frame having a rear end pivotally connected with the movable frame, and a driving member extendable and retractable in length, having a rear end pivotally connected with the movable frame and located below the rear end of the back frame, and a front end pivotally connected with the back frame. A linkage has a front end pivotally connected with the base frame, and a rear end pivotally connected with the back frame and located between the rear end of the back frame and the front end of the driving member. When the driving member extends longer, the back frame is rotated upwardly to enable the rear end of the back frame and the movable frame to horizontally move forward together. | 2016-01-28 |
20160022519 | METHOD OF CONTROLLING A PRESSURIZED MATTRESS SYSTEM FOR A SUPPORT STRUCTURE - A method for automatically varying the internal air pressure in at least one inflatable air bladder associated with at least one zone of a pressurized mattress system to achieve an optimal zone air pressure for a patient. The method includes a step of incrementally decreasing the zone air pressure of the at least one zone until more than a predetermined percentage or portion of the patient is directly supported by a substrate disposed below the at least one inflatable air bladder. The method then determines the appropriate increase in zone air pressure to achieve the optimal zone air pressure for the patient. | 2016-01-28 |
20160022520 | Dynamic Support Apparatus - A dynamic support apparatus. The dynamic support apparatus includes a cushion, at least one actuator wherein the at least one actuator defines an interior volume and wherein the interior volume may be configured to be at least partially filled with a fluid, and a support disposed in the interior volume wherein the support configured to support an occupant when the interior volume is not filled with the fluid such that the support is sufficient to support the occupant. | 2016-01-28 |
20160022521 | CUSHION IMMERSION SENSOR - A sensor for attachment to an inflatable air cell cushion designed to detect optimal immersion of the cushion user into the in the inflatable cushion. The immersion depth of a user positioned on the cushion is determined by sensing air pressure in the cushion. The sensor accurately reads changes in pressure as air exits the cushion to allow an algorithm to determine optimal internal cushion pressure for a user. | 2016-01-28 |
20160022522 | LIFTING DEVICE AND ASSOCIATED METHODS - A lifting device may include a main body member and a top member that is detachably connectable to portions of the main body member. The top member may include a top and a hoist assembly that is connected to and extends outwardly from the top. The lifting device may be used to assist in lifting a patient from a seated or a prone position. The main body member is moveable between a collapsed position that is defined as side support member of the main body member being positioned adjacent to a support connecting member of the main body member, and the opened position is defined as a side support members of the main body member being positioned substantially perpendicular to the support connecting member. | 2016-01-28 |
20160022523 | INTERLOCK VESSEL FOR HYPERBARIC TRANSFER SYSTEM - An interlock vessel having an air-tight body with opposing ends. A portion of the body is designed to fit into a decompression (hyperbaric) chamber, wherein a diver or a patient undergoing a decompression treatment is positioned. The opposing ends are closed by pivotally moveable doors and locking assemblies that retain the doors in a closed position until the pressure inside the decompression chamber and the exterior of the chamber can be equalized. The outer door has two locking systems: (a) an interlock system and (b) a safety/delay locking system. Both locking assemblies are manually operated. | 2016-01-28 |
20160022524 | EXTRACORPOREAL LIFE SUPPORT SYSTEM AND METHODS OF USE THEREOF - Extracorporeal membrane oxygenation systems and methods of use are disclosed. Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Full citations of these references can be found throughout the specification. Each of these citations is incorporated herein by reference as though set forth in full. | 2016-01-28 |
20160022525 | Sensorimotor Discs for Infants and Babies - In one example, we describe a method and system for infant's development, which is a disc system, with various combinations and extensions. The brain is the only organ that constantly reorganizes itself based on experiences or lack thereof. Babies are born with millions of neurons. Through a process called “pruning”, certain ‘circuits’ are fine-tuned through repeated practice and stimulation. This occurs from birth, throughout early childhood. The purpose of the SensiMo Disc is to provide an infant, e.g., typically, up to the 25 lbs. and/or 29 inches long, sensorimotor stimulation, while lying in a prone or supine position, with minimal active movement of the head or extremities. As the child lays supine or proneon, on the SensiMo disc, the child's tactile, vestibular, and proprioceptive systems are stimulated. This helps develop the child's sensorimotor system. Many other variations and combinations, plus advantages, are discussed. | 2016-01-28 |
20160022526 | MOBILE CART AND MEDICAL CART - A mobile cart includes a cabinet, wheels, drawers and an illumining unit. The wheels are disposed on a bottom of the cabinet. The drawers are disposed in the cabinet and configured to be pulled out of the cabinet. The drawers includes compartment drawers. The illumining unit is disposed on a top of the cabinet and includes a compartment drawer illumining module, wherein the compartment drawer illumining module is configured to illumine any one of the compartment drawers being pulled out of the cabinet. | 2016-01-28 |
20160022527 | DEVICE FOR RELIEVING OR PREVENTING LOWER BACK PAIN - A device for treating or preventing lower back pain that is simpler and less costly than previous similar devices. Among the features of the device are a leg rest height adjustment arrangement that is simple to operate and provides substantially continuous height adjustment, a leg rest folding mechanism that pivotally couples the leg rest to a leg rest support shaft to place the leg rest in operative and storage positions, and a flexible cover that does not substantially change its length during height adjustment. | 2016-01-28 |
20160022528 | Compression Device - A wearable massage and/or compression device for applying controllable scrolling or intermittent sequential forces, such as compression forces, to the body and limbs of a user comprises an elongated fabric body sized to encircle a limb of a user, one or more shape-memory wires carried by the fabric body and configured to apply a compression pressure to the limb through the fabric body upon changing shape in response to a stimulus, and a micro-processor based controller for selectively actuating the one or more shape-changing elements to reduce the effective diameter of the device encircling the limb, to thereby apply pressure to the limb. | 2016-01-28 |
20160022529 | MASSAGE DEVICE - A massage device includes spaced apart first and second arms having aligned first and second pivot areas. A cross bar having a first end and a second end is attached to the first arm proximate the first end of the cross bar between the first and second pivot areas. The cross bar is attached to the second arm proximate the second end of the cross bar between the first and second pivot areas. A massage element is carried by the cross bar. | 2016-01-28 |
20160022530 | NEW DIAGNOSTIC AND TREATMENT METHODS - The present invention relates to a method of diagnosing the primary lesions that give rise to a chronic condition or incorrect structure in myofascial units and associated structures in a human patient. The invention also relates to a method of therapeutic treatment of the diagnosed conditions, in particular by application of a variable vaccum stimulus. | 2016-01-28 |
20160022531 | STATIONARY SELF-MASSAGE APPARATUS FOR ATTACHMENT TO VARIOUS STABALIZING SURFACES - A massage device for use on horizontal, vertical, narrow or non-flush stabilizing surfaces is disclosed. The massage device can include a frame having a cavity of a substantially half spherical shape to accommodate a roller ball. A plurality of ball bearings located between the cavity and the roller ball allow the roller ball to rotate as affected by motion from external forces of self-massaging, a massage from another person, or otherwise. A stabilizing mechanism attached to the frame provides stabilization during self-massage. The massage device attaches to horizontal or a vertical flush surface with suction cups, and to a non-flush surface or one that is narrower than the massage device with a strap. | 2016-01-28 |
20160022536 | Therapeutic Method and Apparatus Using Mechanically Induced Vibration - A noninvasive method of treating or preventing pressure ulcers is disclosed. The method includes placing a motorized pad about a subject, activating a plurality of motors positioned in the motorized pad each having an output shaft to thereby cause application of a rotational motion to each of the plurality of motor shafts, converting the rotational motion to a vibrational motion by using a corresponding unbalanced mass with each motor, applying the vibrational motion to a corresponding part of the subject, and damping any vibrational forces substantially parallel to an underlying skin surface more than vibrational forces substantially perpendicular to the underlying skin surface. | 2016-01-28 |
20160022537 | Handling Useful Sauna Equipment - The present invention relates to a handling useful sauna equipment, more particularly a very convenient handling useful sauna equipment, which enables a lower body to move conveniently without a necessity of making the hip sit on a chair component and to enjoy sauna in a convenient posture, and which includes a chair portion that moves to and fro by a to-and-fro delivering means and a backrest fixed to the chair portion. According to the embodiment, since the chair portion is moved by the to-and-fro delivering means, even a handicapped user can position the lower body easily on a heater and use the sauna very easily. | 2016-01-28 |
20160022538 | ASEPTIC CONNECTOR AND METHOD - A method for forming an aseptic connection includes inserting an end of a sealed fill connector into a receptacle of an aseptic connector assembly; moving a pivot portion of the aseptic connector assembly relative to a body portion of the aseptic connector assembly so as to sever a portion of the fill connector, the pivot portion being at least partially disposed within the body portion; and advancing a conduit portion of the aseptic connector assembly into the fill connector so as to form an aseptic connection therebetween, the conduit portion being at least partially disposed within the pivot portion or the body portion of the aseptic connector assembly after advancing. | 2016-01-28 |
20160022539 | A PREFILLED MEDICATION DEVICE, METHOD OF MAKING AND USING THE SAME - The invention generally relates to prefilled disposable medication devices, method of making, and using to store, contain and deliver at least a diluent for allergenic extract and more particularly to a prefilled cartridge containing a diluent for allergenic extract for use with an injection pen for allergy treatments. | 2016-01-28 |
20160022540 | Delivery Device and Storage System for Oropharyngeal Administration of Mother's Colostrum and Milk - A delivery system and method for storing and delivering colostrum or milk to an infant are provided. In one aspect, the system includes a syringe for delivering a dose of colostrum or milk, a swab container, and a swab. The swab is contained in the swab container and the swab container connected to the syringe. In another aspect, the delivery system includes a plurality of syringes for delivering a dose of colostrum or milk and a storage container for storing the plurality of syringes having the colostrum or milk therein. The method includes loading a first syringe with a dose of colostrum or milk and placing the loaded first syringe in a first slot in a storage container. The method further includes loading a second syringe with a dose of colostrum or milk and placing the loaded second syringe in a second slot in the storage container. | 2016-01-28 |
20160022541 | SYSTEM AND METHOD FOR SECURE MEDICATION DISPENSING - A dispenser and vial system is disclosed. At least one vial is loaded into a dispenser to automatically dispense dosages of medication made up of units of medication. The vial stores and releases the units of medication. The dispenser has a delivery mechanism configured to dispense a plurality of units of medication (from one or more vials) to make up a dosage of medication, and trigger or actuate the release of the plurality of units of medication based on information on the at least one vial readable by the dispenser to validate the at least one vial prior to the trigger or actuation by a link between, the dosage of medication, a user or patient and the at least one vial. | 2016-01-28 |
20160022542 | HOME MEDICATION MANAGER - A self medication management system and method comprising at least a plurality of receptacles, a scanner, a display screen, and a processor to acquire medication information from a medication container, determine whether the medication information exists in a first database, if the medication information does not exist in the first database, associate the medication information with a location information comprising a receptacle and store the medication information and the location information in the first database, indicate the location information, and confirm placement of the medication container in the associated receptacle, notify a user to administer the medication held in the medication container, and request the user to scan the medication container of the notified medication, detect retrieval of an incorrect medication container from the plurality of receptacles, and issue a warning of the detection, and provide instructions for administering the medication. | 2016-01-28 |
20160022543 | AS-NEEDED, TIME CONTROLLED MEDICATION DISPENSER AND METHODS - A medication dispenser having a housing adapted to securely retain patient medication until such a time as a controller enables a patient interface to permit a patient to access medication stored and distributed by the dispensing assembly. | 2016-01-28 |
20160022544 | GASTROSTOMY DELIVERY SYSTEM AND METHOD - A method of feeding a patient through the patient's gastrostomy feeding tube. The method includes the steps of connecting a connector of a filled feeding bag directly to a port of the feeding tube; manipulating the feeding bag such that the fluid within the filled feeding bag is driven through the connector and into the feeding tube; and disconnecting the feeding bag connector from the port of the feeding tube after the fluid has been expelled from the feeding bag. | 2016-01-28 |
20160022545 | Detection System for Flow Control Apparatus - A flow control apparatus adapted to receive a feeding set includes a housing capable of receiving at least a portion of the feeding set. A pumping device is supported by the housing and positioned to contact the feeding set when the feeding set is received by the housing so the pumping device acts on the feeding set to produce fluid flow in the feeding set for delivery of fluid to a subject. An ultrasonic sensor is supported by the housing and arranged with respect to the pumping device to produce a sensor signal indicative of a viscosity of the fluid delivered through the feeding set. A control circuit is in communication with the ultrasonic sensor for receiving the sensor signal from the sensor indicative of the viscosity of the fluid and in communication with the pumping device to control operation thereof. | 2016-01-28 |
20160022546 | FLOW DETECTION SYSTEM FOR FLOW CONTROL APPARATUS - A flow control apparatus and method for accurate detection of occlusion conditions in a feeding set. A sensor is arranged with respect to a pumping device to produce a signal indicative of pressure in the feeding set. A control circuit that may receive the sensor signal from the sensor indicative of the pressure in the feeding set may also control operation of the pumping device. The control circuit is configured to operate the pumping device in an operational state, and in a reset state subsequent to the operational state in which the pumping device does not produce a pumping action and the pumping device is moved to a position in which the pumping device does not block the feeding set to permit fluid flow in a backflow direction opposite to the patient direction thereby relieving any built up pressure in the feeding set downstream of the pumping device. | 2016-01-28 |
20160022547 | SOUND SOOTHER - A pacifier or a teething device comprising of a mouth-guard having a body, said body having a front-surface, a back-surface, and a thickness wherein said thickness makes an interior space; a mouth-piece having a proximal end to be placed in a mouth and a distal end connected to said front-surface of said mouth-guard; an instrument embedded in said interior space or being connected to said back-surface of said mouth-guard or being connected to the front-surface of the said teething device; and a handle connected to said back-surface of said mouth-guard or connected to said instrument. | 2016-01-28 |
20160022548 | STABLE DENTAL VARNISH COMPOSITIONS AND METHODS OF MANUFACTURE AND USE - Fluoride varnish compositions for temporary application and adhesion to a person's teeth include a carrier that remains stable and translucent during storage. The compositions include a carrier comprising a stable and translucent resin and a fluoride ion source (e.g., a fluoride salt such as sodium fluoride) dispersed within the carrier so as to provide biologically available fluoride ions to teeth being treated. The carrier resists formation of solids that can plug a 25 gauge or smaller syringe brush applicator tip. The compositions may also include an adhesion promoting agent comprising an alkyl phosphoric acid. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors. | 2016-01-28 |
20160022549 | DENTAL PRIMER FORMULATION - Primer formulation which contains (1) at least one alkoxysilane monomer of the general formula R | 2016-01-28 |
20160022550 | SOLID LIPID NANOPARTICLES (I) - The present invention relates to new (foodgrade) solid lipid nanoparticles, as well as the production of such solid lipid nanoparticles and the use of them. | 2016-01-28 |
20160022551 | Visually Distinctive Multiple Liquid Phase Compositions - A multi liquid phase composition wherein said phases are visually distinctive. These compositions combine multiple phases for creating multipurpose personal care compositions. | 2016-01-28 |
20160022552 | COMPOSITION OF HYDROGEL SOAP, HYDROGEL SOAP AND PREPARING METHOD THEREOF - Composition of a hydrogel soap, a hydrogel soap, and a method of preparing the same. The hydrogel soap represents detergency or moisturizing power superior to that of a general soap and has weak acidity or neutral-pH (pH 5.0 to pH 7.0), so that the skin irritation is mitigated and superior formability is represented. | 2016-01-28 |
20160022553 | TEMPERATURE CHANGE COMPOSITIONS AND TISSUE PRODUCTS PROVIDING A COOLING SENSATION - Wiping products, such as facial tissues, contain a temperature change composition that can provide a cooling sensation when contacted with the skin of a user. The temperature change composition is structured emulsion that may include a phase change material, a carrier, a surfactant, and a crystalline initiator. The phase change materials, in one embodiment, can have a relatively high heat of fusion. When undergoing a phase change, the temperature change composition absorbs heat and thereby provides a cooling feeling or cooling sensation to the skin of a user. | 2016-01-28 |
20160022554 | AGENT FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBRES - The invention relates to a cosmetic composition for the temporary shaping of keratin-containing fibers, including (a) at least one emulsifier (a) from the group of the ethoxylated unsaturated C16-C18 fatty alcohols with an average degree of ethoxylation between 4 and 6; (b) at least one emulsifier (b) from the group of ethoxylated saturated C16-C18 fatty alcohols with an average degree of ethoxylation between 12 and 30, characterized in that the weight ratio of emulsifier (a) to emulsifier (b) ranges from 2:1 to 1:5, preferably from 1:1 to 1:2, and particularly suitable for the temporary shaping of keratin-containing fibers, particularly human hair. | 2016-01-28 |
20160022555 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES - The present disclosure relates, according to some embodiments, to molecules, including conjugated fused polycyclic molecules, that may receive excited state energy from other molecules (e.g., light-absorbing molecules) or directly from the irradiation sources. According to some embodiments, the disclosure relates to molecules, including conjugated fused polycyclic molecules, that may resolve (e.g., quench, dissipate) excited state energy, normally by way of releasing it as heat. (e.g., as heat). Conjugated fused polycyclic molecules of various structures are disclosed including Formula III: | 2016-01-28 |
20160022556 | 1,5-ANHYDRO-D-GLUCITOL-CONTAINING COLLAGEN PRODUCTION ACCELERATOR - A collagen production promoter in cells, containing at least one member selected from the group consisting of 1,5-anhydro-D-glucitol and derivatives thereof; and a composition containing the collagen production promoter. Since the collagen production promoter containing 1,5-AG or derivatives thereof of the present invention is suitably used as cosmetics, medicinal formulations, foods, and the like, for promoting collagen production in cells, for example, preventing and/or improving wrinkles of skin. | 2016-01-28 |
20160022557 | Alkyl Glycoside-Based Micellar Thickeners For Surfactant Systems - A rheology modifier which includes a mixture of short and long chain fatty acid esters is suitable for use in liquid surfactant-based compositions. A surfactant-based composition includes a surfactant, the rheology modifier, and water. The rheology modifier includes a mixture of alkyl glycoside fatty acid esters including a long chain fatty acid ester of an alkyl glycoside and a short chain fatty acid ester of an alkyl glycoside. The long chain fatty acid ester includes at least one fatty acid residue: R | 2016-01-28 |
20160022558 | Hair Treatment Products and Methods for Straightening Hair - Methods and hair treatment products for smoothing or straightening hair having a formulation including at least one reducing agent, at least one protein fraction, at least one emollient, at least one emulsifier; and an aqueous diluent. The hair treatment product having a viscosity of from about 1 to about 1000 cps and a pH of about 1.5 to about 3. | 2016-01-28 |
20160022559 | Stable Silk Protein Fragment Compositions - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2016-01-28 |
20160022560 | Stable Silk Protein Fragment Compositions - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2016-01-28 |
20160022561 | Stable Silk Protein Fragment Compositions - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2016-01-28 |
20160022562 | Stable Silk Protein Fragment Compositions - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2016-01-28 |
20160022563 | Stable Silk Protein Fragment Compositions - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2016-01-28 |
20160022564 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR - Described herein are methods and compositions that contain a soluble polyglucosamine or polyglucosamine derivative for use in oral health. The compositions are useful for, e.g., reducing bacteria (e.g., by clumping and removing) or disrupting a biofilm in the mouth of a subject, reducing dry mouth, and reducing oral inflammation. | 2016-01-28 |
20160022565 | Cosmetic Composition Comprising a Thickening Polymer - A cosmetic composition comprising a thickening polymer, a non-ionic surfactant, a non-ionic kosmotrope and water. Also, a hair colorant formulation obtained from mixing said composition and a hair dye. Also, the use of said formulation for colouring and/or sculpting hair. | 2016-01-28 |
20160022566 | IMPROVED FOAMING PERFORMANCE IN CLEANSING COMPOSITIONS THROUGH THE USE OF NONIONIC, AMPHIPHILIC POLYMERS - The invention relates to a method for improving the foaming and/or yield value properties associated with surfactant containing compositions comprising at least one anionic surfactant, the method comprises combining an effective amount of at least one nonionic, amphiphilic polymer with at least one anionic detersive surfactant in combination with an optional surfactant selected from amphoteric surfactants, nonionic surfactants and combinations of two or more thereof. The at least one nonionic amphiphilic polymer is prepared from a free radically polymerizable monomer composition comprising at least one hydrophilic monomer and at least one hydrophobic monomer, wherein said hydrophilic monomer is selected from a N-vinyl lactam and wherein said hydrophobic monomer is selected from a vinyl ester of a C | 2016-01-28 |
20160022567 | WAXES HAVING OIL-IN-WATER SELF-EMULSIFYING AND WATER GEL-FORMING PROPERTIES, COMPOSITIONS, USES AND METHODS RELATING TO SAME - The present invention relates to waxes useful for cosmetic applications having stable oil-in-water emulsion-forming properties and, in some embodiments, stable gel-in-water-forming properties. In some embodiments, the waxes exhibit self-emulsifying properties, and can be produced without the addition of any other substances to achieve the emulsion (e.g., co-emulsifiers, hydrophilic polymers, polar surfactants, rheological modifiers, gelling agents). The waxes generally comprise: (a) polyglyceryl fatty acid ester, (b) a glycerol fatty acid ester, and 9c) a fatty alcohol. In particular embodiments, the polyglyceryl fatty acid ester can be a polyglyceryl-2, -3, or -4 fatty acid ester, and the fatty chain lengths of (a)-(c) can range from C12 to C22. In more particular embodiments, the waxes can comprise polyglyceryl stearate, glyceryl stearate, and stearyl alcohol. Gels, oil-in-water emulsions, and other compositions produced from the waxes, as well as uses and methods relating thereto, are also disclosed. | 2016-01-28 |
20160022568 | COMPOSITION FOR ORAL CARE - A composition for oral care is proposed, wherein the composition is an aqueous composition and, besides water, comprises at least peppermint oil, rosemary oil and alcohol. In the context of the present invention, it has been found that the composition according to the invention exhibits a surprisingly good effect in the control of biofilms on dental surfaces. Harmful bacteria can no longer accumulate on the dental surfaces. The composition according to the invention can be used for oral and/or dental care and/or for oral prophylaxis, and can be used in particular for dissolving and/or removing extracellular polymeric substances (EPS) on dental surfaces, and/or plaque, and/or tartar, and/or for modifying the pellicle layer on dental surfaces. | 2016-01-28 |
20160022569 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT - A composition comprising lipid and surfactant, characterised in that the surfactant has an HLB number of less than 20 and in that the lipid and surfactant are in the form of macromolecular assemblies of less than 10 nm in diameter. | 2016-01-28 |
20160022570 | MEDICAL IMPLANT - An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device. | 2016-01-28 |
20160022571 | IMPLANTABLE DRUG DELIVERY COMPOSITIONS COMPRISING NON-POLYMERIC SORPTION ENHANCERS AND METHODS OF TREATMENT THEREOF - A drug delivery composition comprises a drug elution rate-controlling excipient comprising an elastomeric polymer defining a reservoir. The reservoir contains at least one discrete solid dosage form comprising at least one active pharmaceutical ingredient (API) and one or more non-polymeric sorption enhancers (e.g., one or more non-polymeric acids, bases, or salts). The drug delivery composition is in an implantable dosage form. A method of treating or preventing one or more diseases or conditions in a subject comprises implanting the drug delivery composition into a subject to systemically deliver a therapeutically effective amount of the API to the subject for a period of time of at least one month at a pseudo-zero order elution rate. | 2016-01-28 |
20160022572 | METHODS, COMPOSITIONS AND DEVICES FOR TREATMENT OF MOTOR AND DEPRESSION SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - Compositions, methods and devices for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods are for treating depression, Parkinson's disease and/or motor and depression symptoms associated with Parkinson's disease, by intranasal administration of an amount of Rasagiline or a pharmaceutically acceptable salt thereof that is sufficient to inhibit depressive illness in the subject and/or is sufficient to inhibit MAO-A in the brain of a subject. | 2016-01-28 |
20160022573 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE - The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone. | 2016-01-28 |
20160022574 | NON-MUCOADHESIVE FILM DOSAGE FORMS - Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided. | 2016-01-28 |
20160022575 | SYSTEM FOR ADMINISTRATION OF CARDIAC PROTECTIVE THERAPY - An dosage member, comprising a planar member comprising a saliva-dissolvable member, a therapeutic agent carried in said planar member, wherein the saliva-dissolvable member is printed or color-coded to indicate potency. A plurality of aspirin containing dissolvable members may each be color-coded to indicate potency, and include a plurality of green dissolvable members and at least one dissolvable member with a color selected from the group consisting of yellow or amber, a red or red like color and a blue or blue like color. Perforations may provided so that higher potency strips may be divided into lower potency dosages. | 2016-01-28 |
20160022576 | METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET - An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 2016-01-28 |
20160022577 | MICRONIZED PHARMACEUTICAL COMPOSITIONS - Described herein are micronized powder particles of colistimethate sodium wherein at least 50% by volume of the micronized particles have a diameter of less than 7 micrometres but not less than 3 micrometres and the powder has a total moisture content of from 5 to 10% by weight, for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistimethate sodium is not separated into component form. The micronized powder particles of colistimethate sodium are useful in the treatment of infections caused by gram-negative bacteria, particularly in patients suffering from cystic fibrosis. | 2016-01-28 |
20160022578 | POLYPEPTIDE BASED BLOCK COPOLYMER AND THE PROCESS FOR THE PREPARATION THEREOF, AND THE POLYMER MICELLES USING THE SAME - The present disclosure relates to a polypeptide based block copolymer having biodegradability due to peptidase, and a process for the preparation thereof, and polymer micelles using the same. The block copolymer according to the present disclosure is a block copolymer of a polyethylene glycol-based compound having properties such that the solubility for water is different depending on the pH, but cannot form micelles due to a self-assembly phenomenon; and a polyglutamic acid-based compound formed using an aminolysis reaction of glutamic acid and tertiary amine in which the end of one alkyl group is substituted with NH | 2016-01-28 |
20160022579 | Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same - A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use. | 2016-01-28 |
20160022580 | LIPID NANOPARTICLES FOR TRANSFECTION AND RELATED METHODS - Transfection reagent composition, lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition. Lipids when dispersed in aqueous media readily form liposomes, such as unilamellar vesicles and multilamellar vesicles. Liposomes have been used successfully to encapsulate and deliver a wide range of chemicals including nucleic acids, proteins and. small molecule drugs, to cells. | 2016-01-28 |
20160022581 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE - Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. | 2016-01-28 |
20160022582 | HIGHLY CONCENTRATED DRUG PARTICLES, FORMULATIONS, SUSPENSIONS AND USES THEREOF - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 2016-01-28 |
20160022583 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION, CONTAINING DONEPEZIL - The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time. | 2016-01-28 |
20160022584 | PHARMACEUTICAL COMPOSITIONS OF GOSERELIN SUSTAINED RELEASE MICROSPHERES - A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly(lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%. | 2016-01-28 |
20160022585 | FORMULATION OF AN ANTIBODY AND USE THEREOF - The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient. | 2016-01-28 |
20160022586 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING CALCIUM - Orally administrable compositions comprising calcium, methods of administration, and methods of making the same. | 2016-01-28 |
20160022587 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. | 2016-01-28 |
20160022588 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 2016-01-28 |
20160022589 | FORMULATION CONTAINING CARBIDOPA, LEVODOPA, AND ENTACAPONE - Disclosed herein are stable pharmaceutical dosage forms containing carbidopa, levodopa, and entacapone. The dosage forms are prepared by mixing carbidopa, levodopa, and entacapone and forming granules. In some embodiments the granules also include starch. Microcrystalline cellulose can be added as an extragranular excipient. The stable pharmaceutical dosage forms have a bioavailability that is substantially similar to a dosage form prepared by adding a substantial portion of carbidopa separately from levodopa and entacapone. | 2016-01-28 |
20160022590 | COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE - Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example. | 2016-01-28 |
20160022591 | EXTENDED RELEASE PHARMACEUTICAL SOLID DOSAGE FORMULATIONS - A solid pharmaceutical dosage form, e.g., a tablet, is disclosed which comprises (a) a sustained released matrix core containing i) an at least sparingly water soluble active pharmaceutical ingredient, ii) a hydrophilic polymer, iii) an optional hydrophobic polymer, iv) an optional wax component, and v) optional diluent; and (b) a semi-permeable functional film coating surrounding the core, wherein the dosage form is substantially resistant to dose dumping when administered in the presence of ethanol. A method for making the dosage form is also provided in which the dosage form is coated with a semi-permeable coating. | 2016-01-28 |
20160022592 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS - The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of | 2016-01-28 |
20160022593 | SEPARABLE CAPSULE - The present disclosure relates to a separable hard capsule for containing a medication. The capsule may be opened by finger force and used, for example, by pediatric and geriatric patients. | 2016-01-28 |
20160022594 | SOFT GEL ENCAPSULATION - A stable soft gel dosage form for micronized magnesium complexes is provided wherein soft gel capsules containing various magnesium complexes can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over an extended period of time. The stable soft gel capsule is sealed at a selected temperature forming a seam in which the gelatin promotes cross-linking across the heat seam. This method of sealing the soft gel provides for a better seal that cures the weeping problem that can result from the prior methods of heat sealing soft gel capsules. | 2016-01-28 |
20160022595 | BIOADHESIVE AND BIODEGRADABLE AND FORMULATIONS THAT PROVIDE SUSTAINED RELEASE OF ANTIMICROBIALS, BACTERIOPHAGES AND ANTI-INFLAMMATORY MEDICATIONS FOR INACTIVATION OF BIOFILMS AND THE TREATMENT OF RHINOSINUSITIS AND OTHER INFECTIONS - Described is a composition comprising one or more active ingredients coated, dispersed, or dissolved with a mucoadhesive polymer. Although subject to multiple uses, the composition, in some embodiments, is usable for treating rhinosinusitis. | 2016-01-28 |
20160022596 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 2016-01-28 |
20160022597 | L-Menthol Dosage Forms Having A Proteinaceous Coating For Enhanced Storage Stability - A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder. | 2016-01-28 |
20160022598 | MULTIFUNCTIONAL NANOPARTICLE DESIGNS AND APPLICATIONS - Methods, structures, devices and systems are disclosed for fabricating and implementing nanoparticles with hollow core and sealable holes. In one aspect, a nanoparticle device can includes a shell structure including at least two layers including an internal layer and an external layer, the internal layer structured to enclose a hollow interior region and include one or more holes penetrating the internal layer, the external layer is of a porous material and formed around the internal layer and sealing the one or more holes, and a substance contained within the hollow interior region, the substance incapable of passing through the external layer. | 2016-01-28 |
20160022599 | System and Method for Fabrication of Uniform Polymer Films Containing Nano and Micro Particles via Continuous Drying Process - The present disclosure provides improved stripfilm based pharmaceutical products (e.g., for enhancing dissolution and bioavailability). More particularly, the present disclosure provides improved systems/methods for fabricating stripfilm based pharmaceutical products by utilizing higher viscosity film forming precursors and drying methods that accomplish improved/faster drying and provide improved/excellent content uniformity of active pharmaceutical agents in the stripfilm based pharmaceutical products. Exemplary systems/methods advantageously use high viscosity, bio-compatible polymeric precursors, (optional use of surface modified drug powders), and convective drying for fabrication of thin films loaded with nano and/or micro sized particles of poorly water-soluble active pharmaceutical ingredients (APIs) to achieve improved active content uniformity and very fast dissolution from poorly water soluble actives, while accomplishing fast drying during the fabrication process. The present disclosure provides for the fast drying (e.g., via low temperature forced convection) of biocompatible polymer films loaded with poorly water-soluble drug nano-particles. | 2016-01-28 |
20160022600 | Enhanced Drug Delivery from Adhesives - Various adhesive compositions are described which comprise one or more active agents such as pharmaceutical agents. The adhesive compositions exhibit enhanced release characteristics. The incorporation of one or more absorbents in particular proportions and/or in conjunction with certain components improves release and release characteristics of active(s). Also described are related methods of improving release of biologically active agents from adhesives and related methods of use of the compositions and articles using such compositions. | 2016-01-28 |
20160022601 | Optical Treatment Methods - A treatment system and method includes use of a chemical facilitator to provide a result-effective event against one or more negative therapeutic effects related to exposing to a light output a skin portion including a condition treatable in whole or in part with light. In one exemplary embodiment for skin treatment including tattoo removal, perfluorodecalin is used to inhibit or resolve whitening, for example to speed a laser therapy session. | 2016-01-28 |
20160022602 | COMPOSITIONS OF BAKUCHIOL AND METHODS OF MAKING THE SAME - The present invention provides compositions of bakuchiol (UP246) having low levels of impurities, particularly furanocoumarin impurities. The present invention further provides improved methods for the isolation, purification and analysis of compositions of bakuchiol. Finally, the present invention provides methods for using the purified bakuchiol compositions and formulations thereof for the prevention and treatment of various diseases and conditions mediated by cyclooxygenase (COX), lipoxygenase (LOX), minor inflammatory conditions and various microbial infections. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. | 2016-01-28 |
20160022603 | NOVEL ANALGESIC COMPOSITIONS - The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In certain embodiments, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration. | 2016-01-28 |
20160022604 | DIRECTLY COMPRESSED OSPEMIFENE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof prepared by direct compression process. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 2016-01-28 |
20160022605 | METHODS FOR REDUCING MICROSATELLITE INSTABILITY INDUCED BY CHEMOTHERAPY AND METHODS FOR SCREENING ANTIOXIDANTS THAT SUPPRESS DRUG-INDUCED MICROSATELLITE INSTABILITY WHILE ENHANCING THE CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS - A therapeutic approach to prevent drug resistance and chemotherapy-related secondary cancer associated with DNA mismatch repair (MMR) deficiency is disclosed based on screening antioxidants for reducing microsatellite instability (MSI) while enhancing the cytotoxicity of chemotherapeutic agents. The work is based on experiments using antioxidants to target reactive oxygen species generated by oxaliplatin, a commonly used chemotherapeutic agent, and is applicable to other chemotherapeutic agent, and in particular 5-fluorouracil, methotrexate, CCNU, etoposide and vinblastine. In particular oxaliplatin is co-treated with an antioxidant, including CDC, CAPE, ciclopirox ethanolamine, hinokitiol, gossypol, n-Octyl caffeate, baicalein, or curcumin. | 2016-01-28 |
20160022606 | NOVEL THERAPY FOR PROSTATE CARCINOMA - Disclosed herein are methods of inhibiting or delaying the growth of androgen-dependent prostate cancer, and/or inhibiting or delaying the onset of castration-resistant prostate cancer (CRPC) by administering naphthoquinone analogs, such as plumbagin, and specified hormone therapy agents, including selective inhibitors of 17,20-lyase activity of CYP 17. | 2016-01-28 |
20160022607 | USES FOR IDEBENONE AND RELATED BENZOQUINONES IN METABOLIC DISORDERS AND OTHER PPAR ALPHA/GAMMA RELATED DISEASES AND CONDITIONS - The present invention relates to the use of a 1,4-benzoquinone derived compound for the treatment of a disease or condition that is associated with peroxisome proliferator activated receptor (PPAR) activity in a mammal. | 2016-01-28 |
20160022608 | Therapeutic Regimens - This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol. | 2016-01-28 |
20160022609 | METHODS FOR TREATING CHRONIC PAIN USING A COMBINATION OF BUPROPION ((.+-.)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND PHENTERMINE (2-METHYL-1-PHENYLPROPAN-2-AMINE) - Methods for treating chronic pain are disclosed. More specifically, methods for treating chronic pain include administering a composition including bupropion and phentermine Methods for treating neuropathic pain and for treating nociceptive pain are further disclosed. | 2016-01-28 |
20160022610 | COMBINATION TREATMENT COMPRISING BUPROPION ( (.+-.)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND A SYMPATHOMIMETIC DRUG FOR WEIGHT CONTROL AND TREATING OBESITY - Compositions and methods for controlling weight gain and treating obesity are disclosed. Compositions include bupropion and a sympathomimetic drug. Methods for controlling weight include administering a composition including a combination of bupropion and a sympathomimetic drug. Methods for treating obesity include administering a composition including a combination of bupropion and a sympathomimetic drug. The active agents of the composition may be administered at a lower dosages than either drug separately with less side effect risk and allow for longer periods of administration to increase the time for controlling weight loss and treating obesity. | 2016-01-28 |
20160022611 | Paediatric Compositions For Treating Multiple Sclerosis - The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C | 2016-01-28 |
20160022612 | OXPRENOLOL COMPOSITIONS FOR TREATING CANCER - The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients. | 2016-01-28 |
20160022613 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof. | 2016-01-28 |
20160022614 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET | 2016-01-28 |
20160022616 | Method for Treating a Pulmonary Disease State in Mammals by Up Regulating Indigenous in vivo Levels of Inflammatory Agents in Mammalian Cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine. | 2016-01-28 |
20160022617 | TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH PROLONGED PHYSICAL INACTIVITY - Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future. | 2016-01-28 |
20160022618 | 4-HYDROXY BENZOATE DERIVATIVES FOR USE IN THE TREATMENT OF INFECTION, INFLAMMATION OR PAIN - A method is described for treatment of a human in need of repeated applications, over a period of time, of smelling salts to provide nasal inhalation of ammonia gas. The method comprises administration to the human as a nasal spray of a therapeutically effective amount of a pharmaceutical composition comprising triethanolammonium 4-hydroxybenzoate dissolved in an aqueous solution within a time interval preceding each application of smelling salts during which the nasal spray remains effective to alleviate or prevent pain to the nasal mucosa caused by the subsequent application of smelling salts. | 2016-01-28 |